| Lonnie Joseph Bargo, MD | |
|
1 Trillium Way, Corbin, KY 40701-8727 | |
| (606) 523-8542 | |
| (606) 523-8708 |
| Full Name | Lonnie Joseph Bargo |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 19 Years |
| Location | 1 Trillium Way, Corbin, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306000591 | NPI | - | NPPES |
| P01462910 | Other | KY | RR MEDICARE |
| 7100056420 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 43375 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Health Corbin | Corbin, KY | Hospital |
| Saint Joseph London | London, KY | Hospital |
| Manchester Memorial Hospital | Manchester, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baptist Health Medical Group Inc | 5597867184 | 1912 |
News Archive
Xenomics, Inc. a developer of trans-renal molecular diagnostic technologies, announced today that it has filed a complaint against Sequenom, Inc. in the Supreme Court of the State of New York alleging that Sequenom fraudulently misrepresented to Xenomics the status of its testing for Down Syndrome and based upon such conduct, Xenomics was induced to enter into a license agreement with Sequenom thereby giving up various valuable patent rights.
Because of undetected toxicity problems, about a third of prescription drugs approved in the U.S. are withdrawn from the market or require added warning labels limiting their use. An exceptionally sensitive toxicity test invented at the University of Utah could make it possible to uncover more of these dangerous side effects early in pharmaceutical development so that fewer patients are given unsafe drugs.
Guanfacine, a medication commonly prescribed to alleviate symptoms of post-traumatic stress disorder, is no more effective than a placebo, according to a study led by researchers at the San Francisco VA Medical Center.
Just as new polls find that voters in three key swing states are more likely to trust President Barack Obama than GOP presumptive nominee Mitt Romney on Medicare, the Romney campaign is struggling to quiet controversies related to this issue.
› Verified 8 days ago
| Entity Name | Baptist Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740586213 PECOS PAC ID: 5597867184 Enrollment ID: O20070228000503 |
News Archive
Xenomics, Inc. a developer of trans-renal molecular diagnostic technologies, announced today that it has filed a complaint against Sequenom, Inc. in the Supreme Court of the State of New York alleging that Sequenom fraudulently misrepresented to Xenomics the status of its testing for Down Syndrome and based upon such conduct, Xenomics was induced to enter into a license agreement with Sequenom thereby giving up various valuable patent rights.
Because of undetected toxicity problems, about a third of prescription drugs approved in the U.S. are withdrawn from the market or require added warning labels limiting their use. An exceptionally sensitive toxicity test invented at the University of Utah could make it possible to uncover more of these dangerous side effects early in pharmaceutical development so that fewer patients are given unsafe drugs.
Guanfacine, a medication commonly prescribed to alleviate symptoms of post-traumatic stress disorder, is no more effective than a placebo, according to a study led by researchers at the San Francisco VA Medical Center.
Just as new polls find that voters in three key swing states are more likely to trust President Barack Obama than GOP presumptive nominee Mitt Romney on Medicare, the Romney campaign is struggling to quiet controversies related to this issue.
› Verified 8 days ago
| Entity Name | Radadvantage A Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376719666 PECOS PAC ID: 2163597899 Enrollment ID: O20090305000655 |
News Archive
Xenomics, Inc. a developer of trans-renal molecular diagnostic technologies, announced today that it has filed a complaint against Sequenom, Inc. in the Supreme Court of the State of New York alleging that Sequenom fraudulently misrepresented to Xenomics the status of its testing for Down Syndrome and based upon such conduct, Xenomics was induced to enter into a license agreement with Sequenom thereby giving up various valuable patent rights.
Because of undetected toxicity problems, about a third of prescription drugs approved in the U.S. are withdrawn from the market or require added warning labels limiting their use. An exceptionally sensitive toxicity test invented at the University of Utah could make it possible to uncover more of these dangerous side effects early in pharmaceutical development so that fewer patients are given unsafe drugs.
Guanfacine, a medication commonly prescribed to alleviate symptoms of post-traumatic stress disorder, is no more effective than a placebo, according to a study led by researchers at the San Francisco VA Medical Center.
Just as new polls find that voters in three key swing states are more likely to trust President Barack Obama than GOP presumptive nominee Mitt Romney on Medicare, the Romney campaign is struggling to quiet controversies related to this issue.
› Verified 8 days ago
| Entity Name | Baptist Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518360296 PECOS PAC ID: 5597867184 Enrollment ID: O20150206000249 |
News Archive
Xenomics, Inc. a developer of trans-renal molecular diagnostic technologies, announced today that it has filed a complaint against Sequenom, Inc. in the Supreme Court of the State of New York alleging that Sequenom fraudulently misrepresented to Xenomics the status of its testing for Down Syndrome and based upon such conduct, Xenomics was induced to enter into a license agreement with Sequenom thereby giving up various valuable patent rights.
Because of undetected toxicity problems, about a third of prescription drugs approved in the U.S. are withdrawn from the market or require added warning labels limiting their use. An exceptionally sensitive toxicity test invented at the University of Utah could make it possible to uncover more of these dangerous side effects early in pharmaceutical development so that fewer patients are given unsafe drugs.
Guanfacine, a medication commonly prescribed to alleviate symptoms of post-traumatic stress disorder, is no more effective than a placebo, according to a study led by researchers at the San Francisco VA Medical Center.
Just as new polls find that voters in three key swing states are more likely to trust President Barack Obama than GOP presumptive nominee Mitt Romney on Medicare, the Romney campaign is struggling to quiet controversies related to this issue.
› Verified 8 days ago
| Entity Name | Mercy Health Physicians Kentucky Specialty Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700408093 PECOS PAC ID: 1456777069 Enrollment ID: O20200813001096 |
News Archive
Xenomics, Inc. a developer of trans-renal molecular diagnostic technologies, announced today that it has filed a complaint against Sequenom, Inc. in the Supreme Court of the State of New York alleging that Sequenom fraudulently misrepresented to Xenomics the status of its testing for Down Syndrome and based upon such conduct, Xenomics was induced to enter into a license agreement with Sequenom thereby giving up various valuable patent rights.
Because of undetected toxicity problems, about a third of prescription drugs approved in the U.S. are withdrawn from the market or require added warning labels limiting their use. An exceptionally sensitive toxicity test invented at the University of Utah could make it possible to uncover more of these dangerous side effects early in pharmaceutical development so that fewer patients are given unsafe drugs.
Guanfacine, a medication commonly prescribed to alleviate symptoms of post-traumatic stress disorder, is no more effective than a placebo, according to a study led by researchers at the San Francisco VA Medical Center.
Just as new polls find that voters in three key swing states are more likely to trust President Barack Obama than GOP presumptive nominee Mitt Romney on Medicare, the Romney campaign is struggling to quiet controversies related to this issue.
› Verified 8 days ago
| Entity Name | Central Valley Imaging Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275523169 PECOS PAC ID: 8628064953 Enrollment ID: O20201120001180 |
News Archive
Xenomics, Inc. a developer of trans-renal molecular diagnostic technologies, announced today that it has filed a complaint against Sequenom, Inc. in the Supreme Court of the State of New York alleging that Sequenom fraudulently misrepresented to Xenomics the status of its testing for Down Syndrome and based upon such conduct, Xenomics was induced to enter into a license agreement with Sequenom thereby giving up various valuable patent rights.
Because of undetected toxicity problems, about a third of prescription drugs approved in the U.S. are withdrawn from the market or require added warning labels limiting their use. An exceptionally sensitive toxicity test invented at the University of Utah could make it possible to uncover more of these dangerous side effects early in pharmaceutical development so that fewer patients are given unsafe drugs.
Guanfacine, a medication commonly prescribed to alleviate symptoms of post-traumatic stress disorder, is no more effective than a placebo, according to a study led by researchers at the San Francisco VA Medical Center.
Just as new polls find that voters in three key swing states are more likely to trust President Barack Obama than GOP presumptive nominee Mitt Romney on Medicare, the Romney campaign is struggling to quiet controversies related to this issue.
› Verified 8 days ago
| Entity Name | Silicon Valley Diagnostic Imaging Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629265806 PECOS PAC ID: 5496838518 Enrollment ID: O20210129001844 |
News Archive
Xenomics, Inc. a developer of trans-renal molecular diagnostic technologies, announced today that it has filed a complaint against Sequenom, Inc. in the Supreme Court of the State of New York alleging that Sequenom fraudulently misrepresented to Xenomics the status of its testing for Down Syndrome and based upon such conduct, Xenomics was induced to enter into a license agreement with Sequenom thereby giving up various valuable patent rights.
Because of undetected toxicity problems, about a third of prescription drugs approved in the U.S. are withdrawn from the market or require added warning labels limiting their use. An exceptionally sensitive toxicity test invented at the University of Utah could make it possible to uncover more of these dangerous side effects early in pharmaceutical development so that fewer patients are given unsafe drugs.
Guanfacine, a medication commonly prescribed to alleviate symptoms of post-traumatic stress disorder, is no more effective than a placebo, according to a study led by researchers at the San Francisco VA Medical Center.
Just as new polls find that voters in three key swing states are more likely to trust President Barack Obama than GOP presumptive nominee Mitt Romney on Medicare, the Romney campaign is struggling to quiet controversies related to this issue.
› Verified 8 days ago
| Entity Name | St Jude Radiology Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649349705 PECOS PAC ID: 7214838002 Enrollment ID: O20210308002102 |
News Archive
Xenomics, Inc. a developer of trans-renal molecular diagnostic technologies, announced today that it has filed a complaint against Sequenom, Inc. in the Supreme Court of the State of New York alleging that Sequenom fraudulently misrepresented to Xenomics the status of its testing for Down Syndrome and based upon such conduct, Xenomics was induced to enter into a license agreement with Sequenom thereby giving up various valuable patent rights.
Because of undetected toxicity problems, about a third of prescription drugs approved in the U.S. are withdrawn from the market or require added warning labels limiting their use. An exceptionally sensitive toxicity test invented at the University of Utah could make it possible to uncover more of these dangerous side effects early in pharmaceutical development so that fewer patients are given unsafe drugs.
Guanfacine, a medication commonly prescribed to alleviate symptoms of post-traumatic stress disorder, is no more effective than a placebo, according to a study led by researchers at the San Francisco VA Medical Center.
Just as new polls find that voters in three key swing states are more likely to trust President Barack Obama than GOP presumptive nominee Mitt Romney on Medicare, the Romney campaign is struggling to quiet controversies related to this issue.
› Verified 8 days ago
| Entity Name | Shps Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790421089 PECOS PAC ID: 7315325933 Enrollment ID: O20220707003956 |
News Archive
Xenomics, Inc. a developer of trans-renal molecular diagnostic technologies, announced today that it has filed a complaint against Sequenom, Inc. in the Supreme Court of the State of New York alleging that Sequenom fraudulently misrepresented to Xenomics the status of its testing for Down Syndrome and based upon such conduct, Xenomics was induced to enter into a license agreement with Sequenom thereby giving up various valuable patent rights.
Because of undetected toxicity problems, about a third of prescription drugs approved in the U.S. are withdrawn from the market or require added warning labels limiting their use. An exceptionally sensitive toxicity test invented at the University of Utah could make it possible to uncover more of these dangerous side effects early in pharmaceutical development so that fewer patients are given unsafe drugs.
Guanfacine, a medication commonly prescribed to alleviate symptoms of post-traumatic stress disorder, is no more effective than a placebo, according to a study led by researchers at the San Francisco VA Medical Center.
Just as new polls find that voters in three key swing states are more likely to trust President Barack Obama than GOP presumptive nominee Mitt Romney on Medicare, the Romney campaign is struggling to quiet controversies related to this issue.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lonnie Joseph Bargo, MD Po Box 1325, Corbin, KY 40702-1325 Ph: (606) 526-8131 | Lonnie Joseph Bargo, MD 1 Trillium Way, Corbin, KY 40701-8727 Ph: (606) 523-8542 |
News Archive
Xenomics, Inc. a developer of trans-renal molecular diagnostic technologies, announced today that it has filed a complaint against Sequenom, Inc. in the Supreme Court of the State of New York alleging that Sequenom fraudulently misrepresented to Xenomics the status of its testing for Down Syndrome and based upon such conduct, Xenomics was induced to enter into a license agreement with Sequenom thereby giving up various valuable patent rights.
Because of undetected toxicity problems, about a third of prescription drugs approved in the U.S. are withdrawn from the market or require added warning labels limiting their use. An exceptionally sensitive toxicity test invented at the University of Utah could make it possible to uncover more of these dangerous side effects early in pharmaceutical development so that fewer patients are given unsafe drugs.
Guanfacine, a medication commonly prescribed to alleviate symptoms of post-traumatic stress disorder, is no more effective than a placebo, according to a study led by researchers at the San Francisco VA Medical Center.
Just as new polls find that voters in three key swing states are more likely to trust President Barack Obama than GOP presumptive nominee Mitt Romney on Medicare, the Romney campaign is struggling to quiet controversies related to this issue.
› Verified 8 days ago
Robin A. Reams, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 1707 Cumberland Falls Hwy, Suite U2, Corbin, KY 40701 Phone: 606-523-2200 Fax: 606-528-6653 | |
Dr. Terri L Daniel-chumbley, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1 Trillium Way, Corbin, KY 40701 Phone: 606-528-1212 | |
Dr. Harold W Reedy, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Trillium Way, Corbin, KY 40701 Phone: 606-528-1212 | |
William T Daniel Ii, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: I Trillium Way, Corbin, KY 40701 Phone: 606-526-8122 Fax: 606-526-9555 |